Ashling Wahner

The United States possesses the highest infant and maternal mortality rates compared with any other high-income country, even though it spends the most on health care.

SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

Authors noted that BiTEs have expanded the treatment paradigms for several types of solid tumors and blood cancers; however, toxicities associated with this class of agents have raised safety concerns.

VXM01 plus avelumab was tolerable and could potentially produce clinically meaningful responses in patients with recurrent glioblastoma.

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer.

Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.